trending Market Intelligence /marketintelligence/en/news-insights/trending/2SQZ2B8OlkgGkg4STbQ1Rg2 content esgSubNav
In This List

Abzena out-licenses antibody technology

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Abzena out-licenses antibody technology

Abzena PLC licensed its ThioBridge technology that links antibodies and other proteins to drugs.

The agreement, with an undisclosed biopharmaceutical company in California, covers the use of the technology for up to 10 antibody drug conjugates for a wide range of indications.

The agreement could net up to $300 million to Abzena in license fees and milestone payments. Abzena would also receive royalties on sales of products that incorporate the technology.